Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 63, Number 10_Supplement_3, S5-S13
Copyright © 2006 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schreck, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schreck, D. M.

Asthma pathophysiology and evidence-based treatment of severe exacerbations

David M. Schreck

DAVID M. SCHRECK, M.D., M.S., FACP, FACEP, is Chairman, Department of Emergency and Hospital Medicine, Summit Medical Group, 80 Division Avenue, Summit, NJ 27599-0001 (dschreck{at}comcast.net).


Purpose. The pathogenesis of asthma and the treatment approach for acute exacerbations are described. The pharmacology, efficacy, safety, and cost of the ß2 agonist, albuterol, a racemic mixture of equal amounts of R- and S-enantiomers, and levalbuterol, the R-enantiomer, are compared.

Summary. Asthma symptoms are the result of bronchial hyperresponsiveness, bronchospasm, and chronic airway inflammation. Short-acting, inhaled ß2 agonists; oxygen; intravenous fluids; and corticosteroids are the mainstays of treatment for acute exacerbations. The R-enantiomer of albuterol is responsible for bronchodilation. The S-enantiomer exhibits broncho-constricting activity in vitro, which may be mediated by muscarinic receptors and may be opposed by adding the anticholinergic agent ipratropium bromide. Levalbuterol improves pulmonary function to a greater extent than racemic albuterol and reduces the need for costly hospitalizations in patients with acute asthma exacerbations.

Conclusion. Levalbuterol is an alternative to racemic albuterol with the potential to improve patient outcomes and reduce costs in the treatment of acute asthma exacerbations.

Index terms: Albuterol; Asthma; Costs; Drug comparisons; Economics; Levalbuterol; Mechanism of action; Steroids, cortico-; Sympathomimetic agents; Toxicity

 



This article has been cited by other articles:


Home page
ANGIOLOGYHome page
I. B. Casella, M. A. Bosch, and C. RD. Sabbag
Incidence and Risk Factors for Bilateral Deep Venous Thrombosis of the Lower Limbs
Angiology, February 1, 2009; 60(1): 99 - 103.
[Abstract] [PDF]


Home page
Am J Health Syst PharmHome page
D. M. Sobieraj
Development and implementation of a program to assess medical patients' need for venous thromboembolism prophylaxis
Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1755 - 1760.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. B. Bauer, D. S. Chun, and T. A. Karpinski
Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital
Am. J. Health Syst. Pharm., September 1, 2008; 65(17): 1643 - 1647.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Health-System Pharmacists.
Advertisement